The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Cabazitaxel Fresenius Kabi 20 mg/ml concentrate for solution for infusion

Fresenius Kabi Deutschland GmbHPA2059/082/001

Main Information

Trade NameCabazitaxel Fresenius Kabi 20 mg/ml concentrate for solution for infusion
Active SubstancesCabazitaxel
Dosage FormConcentrate for solution for infusion
Licence HolderFresenius Kabi Deutschland GmbH
Licence NumberPA2059/082/001

Group Information

ATC CodeL01CD04 cabazitaxel


License statusAuthorised
Licence Issued06/01/2023
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Summary of Product Characteristics, section 4.2).
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back